Berlin, 1st April 2014 – Alacris Theranostics has entered into a project with SAP AG (NYSE: SAP) to use the SAP HANA® platform to enable Alacris‘ proprietary ModCell™ system. Using SAP HANA is expected to accelerate the modelling and prediction of drug action by Alacris‘ ModCellTM system by a factor of several thousand. This allows – in only a few minutes – to identify relevant drugs and simulate their effect on individual patients during cancer treatment, based on highly complex genome and transcriptome data. This speed-up has the potential to be a major factor in helping Alacris bring its ModCellTM applications into a broader clinical use.
Read the full press release here.